An important study has shown that combining blockade of both immune checkpoints (PD-1 and CTLA4) is highly synergistic in rejection of melanoma tumors in an animal model through strong stimulation of effector T cells and IFN-g production [236]. This evidence concerns the gene CTLA4 and melanoma.